Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use DEFENCATH safely and effectively. See full prescribing information for DEFENCATH. DEFENCATH® (taurolidine and heparin) catheter lock solution, for central venous catheter instillation useInitial U.S. Approval: 2023LIMITED POPULATION
Medication labelWhy this: Advisory · dailymed-prescription
LIMITED POPULATION: DEFENCATH® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14)]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.
- generic_name
- taurolidine and heparin
- product_names
- taurolidine and heparin
- ndc
- 72990-103, 72990-103-03, 72990-103-10, 72990-105, 72990-105-05, 72990-105-10
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en